Document Detail


Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
MedLine Citation:
PMID:  22703478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxidative stress and endothelial dysfunction have been associated with essential hypertension (EH) mechanisms. The purpose of this study was to evaluate the effect of carvedilol and nebivolol on the oxidative stress-related parameters and endothelial function in patients with EH. The studied population included 57 patients, either sex, between 30 and 75 years of age, with mild-to-moderate EH complications. Participants were randomized to receive either carvedilol (12.5 mg) (n = 23) or nebivolol (5 mg) (n = 21) for 12 weeks. Measurements included; 24-hr ambulatory blood pressure (BP), flow-mediated dilatation, levels of nitric oxide estimated as nitrite - a nitric oxide metabolite ( NO₂) - in plasma, and oxidative stress-related parameters in plasma and erythrocyte. EH patients who were treated with nebivolol or carvedilol showed systolic BP reductions of 17.4 and 19.9 mmHg, respectively, compared with baseline values (p < 0.01). Diastolic BP was reduced by 13.7 and 12.8 mmHg after the treatment with ebivolol and carvedilol, respectively (p < 0.01) (fig. 2B). Nebivolol and carvedilol showed 7.3% and 8.1% higher endothelium-dependent dilatation in relation to baseline values (p < 0.05). Ferric-reducing ability of plasma (FRAP) and reduced glutathione/oxidized glutathione (GSSH) ratio showed 31.5% and 29.6% higher levels in the carvedilol group compared with basal values; however, nebivolol-treated patients did not show significant differences after treatment. On the other hand, the NO₂ plasma concentration was not modified by the administration of carvedilol. However, nebivolol enhanced these levels in 62.1% after the treatment. In conclusion, this study demonstrated the antihypertensive effect of both beta-blockers. However, carvedilol could mediate these effects by an increase in antioxidant capacity and nebivolol through the raise in NO₂ concentration. Further studies are needed to determine the molecular mechanism of these effects.
Authors:
Ramiro J Zepeda; Rodrigo Castillo; Ramón Rodrigo; Juan C Prieto; Ivonne Aramburu; Solange Brugere; Katia Galdames; Viviana Noriega; Hugo F Miranda
Related Documents :
22900608 - Precision-cut liver slices to investigate responsiveness of deep-sea fish to contaminan...
7446418 - Positive inotropic effects of hydralazine in human subjects: comparison with prazosin i...
22281788 - Relationship of aortic knob width with cardio-ankle vascular stiffness index and its va...
8881838 - Utilization of oxygen by the contractile apparatus is disturbed during reperfusion of p...
20824878 - Respiratory function monitoring to reduce mortality and morbidity in newborn infants re...
6100738 - Sympathetic activation following central vasopressin receptor stimulation in conscious ...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-07-14
Journal Detail:
Title:  Basic & clinical pharmacology & toxicology     Volume:  111     ISSN:  1742-7843     ISO Abbreviation:  Basic Clin. Pharmacol. Toxicol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-15     Completed Date:  2013-03-07     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  101208422     Medline TA:  Basic Clin Pharmacol Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  309-16     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.
Affiliation:
Molecular and Clinical Pharmacology Program, Faculty of Medicine, Biomedical Sciences Institute, Universidad de Chile, Santiago, Chile. rzepeda@ciq.uchile.cl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / adverse effects,  therapeutic use*
Adult
Aged
Antihypertensive Agents / adverse effects,  therapeutic use*
Antioxidants / analysis
Benzopyrans / adverse effects,  therapeutic use*
Carbazoles / adverse effects,  therapeutic use*
Endothelium, Vascular / drug effects*,  metabolism,  physiopathology
Ethanolamines / adverse effects,  therapeutic use*
Female
Glutathione / metabolism
Humans
Hypertension / blood,  drug therapy*,  metabolism,  physiopathology
Male
Middle Aged
Nitric Oxide / blood,  metabolism
Oxidation-Reduction
Oxidative Stress / drug effects*
Propanolamines / adverse effects,  therapeutic use*
Severity of Illness Index
Single-Blind Method
Vasodilator Agents / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Antioxidants; 0/Benzopyrans; 0/Carbazoles; 0/Ethanolamines; 0/Propanolamines; 0/Vasodilator Agents; 030Y90569U/nebivolol; 0K47UL67F2/carvedilol; 10102-43-9/Nitric Oxide; 70-18-8/Glutathione

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carbon Nanostructures Derived Polyaniline Metacomposites: Electrical, Dielectric and Giant Magnetore...
Next Document:  Rapid Coulometric Sodium Chloride Removal System with Nafion Membrane for Seawater Sample Treatment.